Immunodeficiency virus; IQR, interquartile variety; ITT, intent to treat; mITT, modified intent to treat; PMNs/HPF, polymorphonuclear leukocytes per high-powered field.a Owing to missing values, not all variables sum to column totals. Denominators for ITT proportions represent all randomized participants (azithromycin, n = 304; doxycycline, n = 302). Denominators for mITT proportions represent individuals who had data offered for that characteristic. bOther involves Asian (20), Native American or Alaska Native (4), Pacific Islander or Hawaiian Native (four), and a number of (14) for ITT; and Asian (17), Native American or Alaska Native (four), Pacific Islander or Hawaiian Native (three), and several (10) for mITT.cOther consists of unspecified urethral symptoms (70), itching (34), irritation (23), tingling (eight), soreness (7), stinging/burning (six), and also other (12) for ITT; and unspecified urethral symptom (49), itching (26), irritation (17), tingling (7), soreness (four), stinging/burning (five), and other (ten) for mITT. Nonurethral symptoms consist of genital lesion/rash (51), nongenital rash (17), oral/pharyngeal (17), testicular (13), and anorectal (2) for ITT; and genital lesion/rash (38), nongenital rash (14), oral/pharyngeal (14), testicular (9), and anorectal (1) for mITT. Excludes Ureaplasma + unspeciated from denominator of mITT.Pranidipine Cancer This represents guys who were Ureaplasma-positive by culture at the enrollment check out and who could not be speciated at the enrollment or follow-up check out.Clemastine-d5 Purity & Documentation de fg This represents men who have been unfavorable for M.PMID:26895888 genitalium, C. trachomatis, U. urealyticum, and T. vaginalis at enrollment (U. parvum was not deemed a pathogen). hSome includes macrolide (azithromycin; 16), tetracycline (doxycycline; 9), cephalosporin (cefixime, cefpodoxime, ceftriaxone; 6), penicillin (five), fluoroquinolone (ciprofloxacin; three), as well as other antibiotic (6) for ITT, and macrolide (azithromycin; 13), tetracycline (doxycycline; 9), cephalosporin (cefixime, cefpodoxime, ceftriaxone; six), penicillin (three), fluoroquinolone (ciprofloxacin; two), along with other antibiotic (five) for mITT. P = .051. All other comparisons by arm P .05.iMicrobiologic CureIn mITT analyses, the microbiologic cure rate was lower than the clinical remedy price and not drastically unique by arm, with a single exception. In the doxycycline arm, the microbiologiccure rate of C. trachomatis was higher than the clinical cure price (90 vs 76 , P = .06; Table 2). Notably, the microbiologic cure rate was exceptionally low for men with M. genitalium: 40 for azithromycin versus 30 for doxycycline (P = .41).Table 2.Clinical and Microbiologic Remedy at Follow-up inside the Modified Intent-to-Treat Population, by Infection at EnrollmentClinical Cure Azithromycin (n = 216) Doxycycline (n = 206) 76.two (69.81.9) 76.0 (61.86.9) 48.1 (28.78.1) 72.7 (59.03.9) 85.7 (76.62.five) Microbiologic Remedy Azithromycin (n = 216) … 86.3 (73.74.three) 39.5 (24.06.6) 75.0 (61.16.0) … Doxycycline (n = 206) … 90.0 (78.26.7) 29.6 (13.80.2) 69.1 (55.20.9) …All participants Chlamydia trachomatis a Mycoplasma genitalium b Ureaplasma urealyticum c Idiopathicda b c d79.6 (73.64.eight) 86.8 (74.74.five) 63.two (46.08.two) 82.7 (69.71.8) 79.0 (68.57.3)Data are presented as (95 self-assurance interval). Denominator sample size: azithromycin, n = 53 for clinical cure and n = 51 for microbiologic cure; doxycycline, n = 50. Denominator sample size: azithromycin, n = 38; doxycycline, n = 27. Denominator sample size: azithromycin, n = 52; doxycycline, n = 55. Denominator sample si.
